TRANSCELERATE BIOPHARMA INC: Form 990, tax year 2017
View the entire original 990 at ProPublica ↗
- Organization
- TRANSCELERATE BIOPHARMA INC (EIN 46-0886344)
- Tax period
- 2017-01-01 to 2017-12-31
- Filed
- 2018-05-08
- IRS object ID
- 201821289349300512
- Schema version
- 2017v2.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2018-05-08T08:02:13-05:00 | ReturnTs |
| Tax Period End | 2017-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 131639826 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | EISNERAMPER LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 130 NORTH 18TH STREET SUITE 3000 | AddressLine1Txt |
| City | PHILADELPHIA | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 191032757 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2017-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 460886344 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | TRAN | BusinessNameControlTxt |
| Phone | 4845391230 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 100 FOUR FALLS CORP CENTER NO 655 | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DALVIR GILL PHD | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 4845391230 | PhoneNum |
| Signature | 2018-05-04 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | HELEN M MARTIN | PreparerPersonNm |
| PTIN | P01330899 | PTIN |
| Phone | 2158818800 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2017 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | DALVIR GILL PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 100 FOUR FALLS CORP CENTER NO 655 | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $26,172,580 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c | Yes (X) | Organization501cInd |
| Website Address | WWW.TRANSCELERATEBIOPHARMAINC.COM | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2012 | FormationYr |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Activity Or Mission | IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES. THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 20 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 19 | VotingMembersIndependentCnt |
| Total Employee | 14 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $0 | PYContributionsGrantsAmt |
| CY Contributions Grants | $0 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $20,620,000 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $26,133,333 | CYProgramServiceRevenueAmt |
| PY Investment Income | $59,184 | PYInvestmentIncomeAmt |
| CY Investment Income | $39,247 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $20,679,184 | PYTotalRevenueAmt |
| CY Total Revenue | $26,172,580 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $5,000 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $0 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $3,631,766 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $4,790,088 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $20,096,938 | PYOtherExpensesAmt |
| CY Other Expenses | $24,485,225 | CYOtherExpensesAmt |
| PY Total Expenses | $23,733,704 | PYTotalExpensesAmt |
| CY Total Expenses | $29,275,313 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$3,054,520 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$3,102,733 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $44,721,813 | TotalAssetsBOYAmt |
| Total Assets EOY | $43,979,845 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $28,468,410 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $30,831,873 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $16,253,403 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $13,147,972 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | TRANSCELERATE BIOPHARMA INC. IS DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES.THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM CONVERSATIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DISCUSS CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING COMMON CHALLENGES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $23,091,852 | ExpenseAmt |
| Revenue | $26,133,333 | RevenueAmt |
| Desc | IN 2017, TRANSCELERATE DELIVERED THE FOLLOWING ACCOMPLISHMENTS:CLINICAL DATA STANDARDS: CONTINUED TO PARTNER WITH THE STANDARD-SETTING ORGANIZATION CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM, INC. TO DELIVER INDUSTRY-WIDE THERAPEUTIC AREA STANDARDS IN THE AREAS OF SCHIZOPHRENIA AND INFLUENZA.CLINICAL DATA TRANSPARENCY: PUBLISHED 3 NEW RESEARCH PUBLICATIONS AND IMPLEMENTATION TOOLS, ALL PUBLICLY AVAILABLE ON THE TRANSCELERATE WEBSITE. CLINICAL RESEARCH ACCESS & INFORMATION EXCHANGE: PUBLISHED TWO PAPERS IN DIA'S TIRS JOURNAL (IMPROVING INVESTIGATIVE SITE CONTACT OPTIONS ON CLINICAL TRIAL REGISTRIES, AND IMPROVING INFORMATION EXCHANGE WITH CLINICAL TRIAL PARTICIPANTS) AND LAUNCHED A REGISTRY OF THE FUTURE PROPOSAL, ALL PUBLICLY AVAILABLE ON THE TRANSCELERATE WEBSITE. COMMON PROTOCOL TEMPLATE: ACHIEVED ALIGNMENT WITH FDA/NIH, DELIVERED PROOF OF CONCEPT FOR AUTOMATION, AND DELIVERED RELEASE 5.0 OF THE COMMON PROTOCOL TEMPLATE WHICH INCLUDES ENHANCED FEATURES, AND ADDITIONAL TA LIBRARIES.ECONSENT: DELIVERY OF ECONSENT ASSETS TO INDUSTRY (INCLUDING IMPLEMENTATION GUIDANCE AND LANDSCAPE ASSESSMENT) PUBLICLY AVAILABLE ON THE TRANSCELERATE WEBSITE. ELABELS: DEVLIERED CONCEPTUAL WIREFRAME AND IMPLEMENTATION GUIDANCE, PUBLICLY AVAILABLE ON THE TRANSCELERATE WEBSITE. ELABEL PILOTS COMMENCED AT 4 MEMBER COMPANIES.ESOURCE: ESOURCE PUBLISHED TECHNOLOGY LANDSCAPE PAPER, COMPLETED A CONNECTATHON (THROUGH HL7) & ROUNDTABLE WITH HEALTH AUTHORITIES, ACADEMIA AND INVESTIGATOR SITES.INTERPRETATION OF PHARMACOVIGILANCE REGULATIONS: DEVELOPED PERSPECTIVE FOR INTERPRETATION OF AMBIGUOUS IND SAFETY REGULATIONS.INVESTIGATOR REGISTRY: 11 TRANSCELERATE MEMBERS PARTICIPATING, AND ACTIVELY SHARING INVESTIGATOR BACKGROUND INFORMATION.PLACEBO STANDARD OF CARE: CONTINUED DELIVERY OF CONVERTED DATA (109 TRIALS CURRENTLY) WITH MORE THAN 78,000 PATIENTS ACROSS 13 DISEASE AREAS.RISK BASED MONITORING: LAUNCHED THE RBM INTERACTIVE GUIDE.SHARED INVESTIGATOR PLATFORM: LAUNCHED 4 ADDITIONAL RELEASES TO ENHANCE SITE CAPABILITIES.VALUE OF SAFETY INFORMATION DATA SOURCES: DEVELOPED HIERARCHY OF VALUE HYPOTHESIS AND COLLECTED DATA TO SUPPORT THEIR HYPOTHESIS AND COMMENCED DISCUSSION WITH HEALTH AUTHORITIES REGARDING SAME.ADDITIONALLY, IN DECEMBER 2017 THE TRANSCELERATE BOARD OF DIRECTORS APPROVED THE FOLLOWING NEW WORK AREAS: - ADVANCING SAFETY ANALYTICS: THIS PROJECT WILL FOCUS ON DEVELOPING BEST PRACTICES AND GUIDANCE AROUND THE APPLICATION OF INTERROGATIVE METHODS TOWARDS VARIOUS SAFETY DATA SOURCES. - COMMON REGISTRY DATA PACKET: GUIDANCE ON AUTHORING AND PROCEDURAL BEST PRACTICES FOR SPONSORS TO ENSURE THE AVAILABILITY OF COMPLETE, ACCURATE, TIMELY, AND LAY AUDIENCE-FRIENDLY ("QUALITY") INFORMATION AND TO IMPROVE DATA RE-USABILITY. - COMMON SAP TEMPLATE: A COMMON STATISTICAL ANALYSIS PLAN (SAP) TEMPLATE WOULD PROVIDE A MODEL LAYOUT AND CONTENT FOR SAP DOCUMENTATION AND WOULD LINK DIRECTLY TO TRANSCELERATE'S COMMON PROTOCOL TEMPLATE (CPT). - DATA MONITORING COMMITTEE: DEVELOP A FRAMEWORK/TOOLKIT FOR SPONSORS TO USE TO INCREASE THE POPULATION OF PEOPLE WITH REQUISITE SKILLS TO SERVE ON A DATA MONITORING COMMITTEE. - INTELLIGENT AUTOMATION OPPORTUNITIES: THIS PROJECT WILL FOCUS ON IDENTIFYING HOW INTELLIGENT AUTOMATION TECHNOLOGIES CAN BE USED TO SUPPORT EXECUTION OF PV ACTIVITIES/PROCESSES. BY CONDUCTING AN IMPACT ASSESSMENT AND WORKING WITH GLOBAL HEALTH AUTHORITIES TO VERIFY RISKS/ISSUES WITH THEIR USE, THIS INITIATIVE WILL PROVIDE GUIDANCE ON APPROPRIATE APPLICATIONS OF NEW TECHNOLOGY IN PV PRACTICE. - MODERNIZATION OF DIGITAL DATA FLOW: TO RECOGNIZE THE BENEFITS OF TRUE END-TO-END DATA FLOW THE FOLLOWING STEPS MUST BE COMPLETED: A RE-ENGINEERED PROCESS AND ACCOMPANYING METHODOLOGY; DIGITIZATION OF PRIORITIZED PROCEDURES. - PROTOCOL DEVIATIONS : CREATE AND OBTAIN FEEDBACK FROM HEALTH AUTHORITIES ON A FLEXIBLE BEST PRACTICE TOOLKIT AND FRAMEWORK FOR THE COLLECTION, MANAGEMENT AND REPORTING OF PROTOCOL DEVIATIONS. | Desc |
| Total Program Service Expenses | $23,091,852 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | 0 | DescribedInSection501c3Ind |
| Schedule B Required | 0 | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Subject To Proxy Tax | Yes (1) | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | 0 | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | 0 | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 30 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 14 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 20 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 19 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | 0 | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | 0 | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANTHONY GARGES HEAD OF FINANCE AND CONTRACTS | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 4845391235 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 100 FOUR FALLS CORP CENTER SUITE | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (28 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| ELLIOTT LEVY | ||||||||
| CHAIR OF BOARD OF DIRECTOR | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DAVID NICHOLSON | ||||||||
| VICE CHAIR OF BOARD OF DIR | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ALISE REICIN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| BADHRI SRINIVASAN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| BERNHARDT ZEIHER | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| CHRISTOPHER CORSICO | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ELIAS ZERHOUNI | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| IRIS LOEW-FRIEDRICH | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| JAN LUNDBERG | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| KATE OWEN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| KATHY ROUAN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MICHELLE ROHRER | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| PAUL STOFFELS | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| PETER KRISTENSEN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ROB SCOTT | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ROD MACKENZIE | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ROY BAYNES | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| SEAN BOHEN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| TAKUKO YAMADA-SAWADA | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DALVIR GILL | ||||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $1,616,168 | $0 | $53,420 | Yes (X) | ||
| ULO PALM | ||||||||
| CORPORATE SECRETARY | 0.50 | $0 | $0 | $0 | Yes (X) | |||
| ANDREW LEE | ||||||||
| TREASURER | 0.50 | $0 | $0 | $0 | Yes (X) | |||
| JANICE CHANG | ||||||||
| SENIOR VICE PRESIDENT OF GLOBAL OPERATIONS | 40.00 | $449,932 | $0 | $36,349 | Yes (X) | |||
| JENNIFER A BURGESS | ||||||||
| EXECUTIVE DIRECTOR OF COMMUNICATIONS & ENGAGEMENT | 40.00 | $283,235 | $0 | $36,913 | Yes (X) | |||
| CARA L RINALDI | ||||||||
| SENIOR DIRECTOR OF PORTFOLIO MANAGEMENT | 40.00 | $231,401 | $0 | $40,831 | Yes (X) | |||
| ANTHONY GARGES | ||||||||
| HEAD OF FINANCE AND CONTRACTS | 40.00 | $182,625 | $0 | $23,621 | Yes (X) | |||
| JENEEN DONADEO | ||||||||
| DIRECTOR, PROGRAM MANAGEMENT | 40.00 | $176,788 | $0 | $18,947 | Yes (X) | |||
| DENISE REYES | ||||||||
| ASSOCIATE DIRECTOR, PROGRAM MANAGEMENT | 40.00 | $176,418 | $0 | $16,795 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,116,567 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $226,876 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 10 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| ACCENTURE LLP | |||||||||
| 161 N CLARK STREET | CHICAGO | IL | 60601 | CONSULTING & IT SERVICES | $6,781,394 | ||||
| COGNIZANT | |||||||||
| 211 QUALITY CIRCLE | COLLEGE STATION | TX | 77845 | IT SERVICES | $5,867,259 | ||||
| KILPATRICK TOWNSEND | |||||||||
| 601 14TH STREET NW SUITE 900 | WASHINGTON | DC | 20005 | LEGAL SERVICES | $2,363,669 | ||||
| KINAPSE LIMITED | |||||||||
| CONSULTING | $1,013,141 | 27-37 ST GEORGES ROAD | LONDON | UK | SW194 4EU | ||||
| YOH SERVICES LLC | |||||||||
| PO BOX 654068 | DALLAS | TX | 75265 | CONSULTING | $998,050 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 17 | CntrctRcvdGreaterThan100KCnt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MEMBERSHIP DUES | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $26,133,333 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $26,133,333 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $26,133,333 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $39,247 | TotalRevenueColumnAmt |
| Exclusion | $39,247 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $26,172,580 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $26,133,333 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $39,247 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,155,870 | TotalAmt |
| Management And General | $2,155,870 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,141,662 | TotalAmt |
| Program Services | $1,069,766 | ProgramServicesAmt |
| Management And General | $1,071,896 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $70,935 | TotalAmt |
| Program Services | $32,756 | ProgramServicesAmt |
| Management And General | $38,179 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $256,896 | TotalAmt |
| Program Services | $10,914 | ProgramServicesAmt |
| Management And General | $245,982 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $164,725 | TotalAmt |
| Program Services | $58,598 | ProgramServicesAmt |
| Management And General | $106,127 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,389,156 | TotalAmt |
| Program Services | $1,863,649 | ProgramServicesAmt |
| Management And General | $525,507 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $117,074 | TotalAmt |
| Management And General | $117,074 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,927,209 | TotalAmt |
| Program Services | $17,032,691 | ProgramServicesAmt |
| Management And General | $894,518 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $84,638 | TotalAmt |
| Program Services | $30,100 | ProgramServicesAmt |
| Management And General | $54,538 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $167,427 | TotalAmt |
| Program Services | $446 | ProgramServicesAmt |
| Management And General | $166,981 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,740,843 | TotalAmt |
| Program Services | $2,616,310 | ProgramServicesAmt |
| Management And General | $124,533 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $137,550 | TotalAmt |
| Management And General | $137,550 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $403,733 | TotalAmt |
| Program Services | $203,405 | ProgramServicesAmt |
| Management And General | $200,328 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $307,993 | TotalAmt |
| Program Services | $135,892 | ProgramServicesAmt |
| Management And General | $172,101 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,051 | TotalAmt |
| Management And General | $2,051 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $109,419 | TotalAmt |
| Management And General | $109,419 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| RECRUITING | $87,860 | $37,240 | $50,620 |
| FACILITIES COSTS | $5,661 | $5,661 | |
| DUES | $2,486 | $85 | $2,401 |
| BOOKS, SUBSCRIPTIONS, R | $2,050 | $2,050 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $75 | TotalAmt |
| Management And General | $75 | ManagementAndGeneralAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $29,275,313 | TotalAmt |
| Program Services | $23,091,852 | ProgramServicesAmt |
| Management And General | $6,183,461 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,026,630 | BOYAmt |
| EOY | $2,926,545 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $21,694,408 | BOYAmt |
| EOY | $12,842,533 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,833,333 | BOYAmt |
| EOY | $23,100,000 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $153,031 | BOYAmt |
| EOY | $101,107 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $14,458 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $13,946 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,564 | BOYAmt |
| EOY | $512 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $4,997,301 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,847 | BOYAmt |
| EOY | $11,847 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $44,721,813 | BOYAmt |
| EOY | $43,979,845 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,135,077 | BOYAmt |
| EOY | $5,731,873 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $23,333,333 | BOYAmt |
| EOY | $25,100,000 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $28,468,410 | BOYAmt |
| EOY | $30,831,873 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,253,403 | BOYAmt |
| EOY | $13,147,972 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,253,403 | BOYAmt |
| EOY | $13,147,972 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $44,721,813 | BOYAmt |
| EOY | $43,979,845 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$3,102,733 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$2,698 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | 0 | FSAuditedInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantially All Dues Nonded | 0 | SubstantiallyAllDuesNondedInd |
| Only In House Lobbying | Yes (1) | OnlyInHouseLobbyingInd |
| Agree Carryover Prior Year | 0 | AgreeCarryoverPriorYearInd |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $4,202 | OtherCostOrOtherBasisAmt |
| Depreciation | $4,202 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,256 | OtherCostOrOtherBasisAmt |
| Depreciation | $9,744 | DepreciationAmt |
| Book Value | $512 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $512 | TotalBookValueLandBuildingsAmt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DALVIR GILL | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $572,372 | $0 | $1,043,796 | $0 | $0 | $0 | $10,800 | $0 | $42,620 | $0 | $1,669,588 | $0 | $0 | $0 |
| JANICE CHANG | ||||||||||||||
| SENIOR VICE PRESIDENT OF GLOBAL OPER | $361,446 | $0 | $88,486 | $0 | $0 | $0 | $10,800 | $0 | $25,549 | $0 | $486,281 | $0 | $0 | $0 |
| JENNIFER A BURGESS | ||||||||||||||
| EXECUTIVE DIRECTOR OF COMMUNICATIONS | $228,897 | $0 | $54,338 | $0 | $0 | $0 | $10,800 | $0 | $26,113 | $0 | $320,148 | $0 | $0 | $0 |
| CARA L RINALDI | ||||||||||||||
| SENIOR DIRECTOR OF PORTFOLIO MANAGEM | $193,401 | $0 | $38,000 | $0 | $0 | $0 | $9,310 | $0 | $31,521 | $0 | $272,232 | $0 | $0 | $0 |
| ANTHONY GARGES | ||||||||||||||
| HEAD OF FINANCE AND CONTRACTS | $148,256 | $0 | $34,369 | $0 | $0 | $0 | $7,332 | $0 | $16,289 | $0 | $206,246 | $0 | $0 | $0 |
| JENEEN DONADEO | ||||||||||||||
| DIRECTOR, PROGRAM MANAGEMENT | $166,788 | $0 | $10,000 | $0 | $0 | $0 | $7,117 | $0 | $11,830 | $0 | $195,735 | $0 | $0 | $0 |
| DENISE REYES | ||||||||||||||
| ASSOCIATE DIRECTOR, PROGRAM MANAGEME | $139,668 | $0 | $36,750 | $0 | $0 | $0 | $7,070 | $0 | $9,725 | $0 | $193,213 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | THE TRANSCELERATE EXECUTIVE COMMITTEE PREPARES AND APPROVES THE COMPENSATION PACKAGE OF THE CEO. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 4 | DURING 2017, THE BOARD OF DIRECTORS AND MEMBERS OF THE CORPORATION APPROVED AMENDING AND RESTATING THE CERTIFICATE OF INCORPORATION OF THE CORPORATION, IN ORDER TO UPDATE THE PURPOSE CLAUSE TO MORE ACCURATELY ENCOMPASS THE CORPORATION'S CURRENT AND PLANNED ACTIVITIES. THE CORPORATION'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION WAS FILED IN DELAWARE EFFECTIVE AS OF DECEMBER 5, 2017. PRIOR TO THIS AMENDMENT, THE FIRST PARAGRAPH OF ARTICLE III OF THE CORPORATION'S CERTIFICATE OF INCORPORATION PREVIOUSLY READ AS FOLLOWS: "THE CORPORATION IS ORGANIZED EXCLUSIVELY FOR THE PURPOSE OF PROMOTING A COMMON BUSINESS INTEREST WITHIN THE MEANING OF SECTION 501(C)(6) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"), AND, IN PARTICULAR, FOR THE PURPOSE OF PROVIDING LEADERSHIP, PROJECT MANAGEMENT, AND GOVERNANCE DESIGNED TO IMPROVE THE QUALITY OF, AND REDUCE COSTS IN, CLINICAL TRIAL EXECUTION BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES WITHIN THE LIFE SCIENCES INDUSTRY, AND CONSISTENT WITH THAT PURPOSE, TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH NON-STOCK, NONPROFIT CORPORATIONS MAY BE ORGANIZED UNDER THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE (THE "DGCL"). THE CORPORATION SHALL BE A NONPROFIT CORPORATION." FOLLOWING THIS AMENDMENT, THE FIRST PARAGRAPH OF ARTICLE III OF THE CORPORATION'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NOW READS AS FOLLOWS: "THE CORPORATION IS ORGANIZED EXCLUSIVELY FOR THE PURPOSE OF PROMOTING A COMMON BUSINESS INTEREST WITHIN THE MEANING OF SECTION 501(C)(6) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"), AND, IN PARTICULAR, FOR THE PURPOSE OF PROVIDING LEADERSHIP, PROJECT MANAGEMENT, AND GOVERNANCE RELATING TO INDUSTRY COLLABORATIONS DESIGNED TO IMPROVE THE EFFICIENCY OF RESEARCH AND DEVELOPMENT INITIATIVES AND ACTIVITIES IN THE AREAS OF PRECLINICAL RESEARCH, CLINICAL TRIAL EXECUTION, AND PHARMACOVIGILANCE, UNDERTAKEN BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES WITHIN THE LIFE SCIENCES INDUSTRY, AND CONSISTENT WITH THAT PURPOSE, TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH NON-STOCK, NONPROFIT CORPORATIONS MAY BE ORGANIZED UNDER THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE (THE "DGCL"). THE CORPORATION SHALL BE A NONPROFIT CORPORATION." AMENDMENT OF BYLAWS: DURING 2017, THE BOARD OF DIRECTORS OF THE CORPORATION APPROVED AMENDING THE BYLAWS OF THE CORPORATION TO INCREASE THE NUMBER OF AT-LARGE TIER I DIRECTORS FROM 2 TO 3, AND TO INCREASE THE MAXIMUM NUMBER OF MEMBERS OF THE BOARD OF DIRECTORS FROM 20 TO 21. SECTION 3.02 OF THE BYLAWS NOW READS AS FOLLOWS: "SECTION 3.02 NUMBER AND COMPOSITION OF DIRECTORS. THE NUMBER OF DIRECTORS SHALL BE DETERMINED BY RESOLUTION OF THE BOARD OF DIRECTORS ADOPTED BY THE AFFIRMATIVE VOTE OF DIRECTORS CONSTITUTING A MAJORITY OF THE TOTAL NUMBER OF DIRECTORS IN OFFICE AT THE TIME OF SUCH VOTE. THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-ONE (21) MEMBERS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS (AND EACH CHARTER MEMBER HAS DISCRETION TO APPOINT ITS OWN REPRESENTATIVE TO THE BOARD OF DIRECTORS ("CHARTER MEMBER DIRECTORS"); (II) UP TO THREE (3) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS ("AT LARGE TIER I DIRECTORS") (CHARTER MEMBER DIRECTORS AND AT LARGE TIER I DIRECTORS COLLECTIVELY SHALL BE REFERRED TO AS "TIER I DIRECTORS"); (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS ("TIER II DIRECTORS"); (III) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS ("ASSOCIATE MEMBER DIRECTOR"); AND (IV) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION ("CEO DIRECTOR"). THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, SHALL AT ALL TIMES REPRESENT AT LEAST 55% OF THE TOTAL NUMBER OF DIRECTORS OF THE BOARD. IN THE EVENT THAT THE NUMBER OF DIRECTORS IS INCREASED, THEN THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, AND THE BOARD SEATS RESERVED FOR THE TIER II MEMBERS SHALL BE INCREASED IN THE SAME RATIO AS SET FORTH ABOVE." |
| FORM 990, PART VI, SECTION A, LINE 6 | THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER I MEMBERS ARE FURTHER DEFINED AS THE "CHARTER MEMBERS." B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-ONE (21) MEMBERS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS; (II) UP TO THREE (3) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS; (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS; (IV) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS; AND (V) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION. THE CORPORATION'S BYLAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I AT-LARGE DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. TRANSCELERATE DOES NOT PRESENTLY HAVE ANY ASSOICATE MEMBERS THEREFORE, THE ASSOICATE MEMBER BOARD SEAT IS CURRENTLY VACANT. EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 15 | FOR 2017, THE TRANSCELERATE EXECUTIVE COMMITTEE PREPARED AND APPROVED THE COMPENSATION PACKAGE FOR THE CEO. HOWEVER, THE TRANSCELERATE EXECUTIVE COMMITTEE HAS BEEN DISBANDED EFFECTIVE AS OF JANUARY 1, 2018; THUS, FOR 2018 AND GOING FORWARD, THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, WILL REVIEW AND RECOMMEND THE CEO'S COMPENSATION PACKAGE FOR APPROVAL BY THE FULL BOARD. THE CEO APPROVES THE COMPENSATION FOR THE SENIOR VICE PRESIDENT OF GLOBAL OPERATIONS, ALONG WITH ALL OTHER KEY EMPLOYEES. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY AND OTHER CORPORATE POLICIES ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART IX, LINE 11G | EXTERNAL CONTRACTOR SUPPORT: PROGRAM SERVICE EXPENSES 9,957,568. MANAGEMENT AND GENERAL EXPENSES 56,165. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,013,733. PROJECT MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 6,581,082. MANAGEMENT AND GENERAL EXPENSES 402,875. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 6,983,957. COMMUNICATIONS FEES: PROGRAM SERVICE EXPENSES 494,041. MANAGEMENT AND GENERAL EXPENSES 435,478. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 929,519. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp
Disregarded Entity Name DisregardedEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BIOCELERATE LLC | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 100 FOUR FALLS CORP CENTER SUITE 65 | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 475492971 | EIN |
| Primary Activities | TO IMPROVE EFFICIENCIES IN PRECLINICAL RESEARCH. | PrimaryActivitiesTxt |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Total Income | $2,333,333 | TotalIncomeAmt |
| End Of Year Assets | $2,991,069 | EndOfYearAssetsAmt |
Direct Controlling Entity Name DirectControllingEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1Txt |